Key Product Details
Product Summary for Human CXCL13/BLC/BCA‑1 Biotinylated Antibody
Accession # Q53X90
Applications for Human CXCL13/BLC/BCA‑1 Biotinylated Antibody
Sample: Recombinant Human CXCL13/BLC/BCA‑1 (Catalog # 801-CX)
Human CXCL13/BLC/BCA-1 Sandwich Immunoassay
Read 3 publications using BAF801 in the following applications:
Formulation, Preparation and Storage
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23 - 34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA-1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.
Product Specific Notices for Human CXCL13/BLC/BCA‑1 Biotinylated Antibody
For research use only